Prosecution Insights
Last updated: October 04, 2026
Application No. 17/914,559

LOW-MIGRATION HINDERED PHENOL ANTIOXIDANT COMPOUND, PREPARATION METHOD AND COMPOSITION

Non-Final OA §112
Filed
Sep 26, 2022
Priority
Mar 26, 2020 — CN 202010222099.5 +1 more
Examiner
WARD, PAUL V
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jerry Tseng
OA Round
2 (Non-Final)
83%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allowance Rate
1417 granted / 1704 resolved
+23.2% vs TC avg
Minimal -12% lift
Without
With
+-12.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
60 currently pending
Career history
1729
Total Applications
across all art units

Statute-Specific Performance

§101
5.4%
-34.6% vs TC avg
§103
20.4%
-19.6% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
42.3%
+2.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1704 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION STATUS OF THE CLAIMS: Claims 1-9 are pending in this application. Specification The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors and grammatical errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Claim Objections Claims 2-9 are objected to because of the following informalities: (a) In claim 2, last line, amend claim to read “oxygen, sulfur or nitrogen.” (b) In claims 6-8, last line, the claims should be amended to add “and” or “or” between the last two variable. (c ) In claim 9, last line, the claims should be amended to add “and” or “or” between the last two structures. Examiner notes that the claims are generally narrative and and/or fails to conform with current U.S. practice. They appear to be replete with grammatical and idiomatic errors. Additionally, Examiner suggests amending the Specification and claims to correct grammatical and idiomatic errors, and to conform with current U.S. practice. Claim Rejections - 35 USC § 112, 2nd paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3-5 (included claims dependent thereon and claims that relate back to claim 4) are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. (a) Claim 3 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, for being indefinite because claim 3 is a dependent claim of claim 2, which contains formula (1), but claim 3 recites “the compound of formula I” and the structure is labeled “II”. Appropriate correction is required. (b ) Claim 4 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, for being indefinite because claim 3 is a dependent claim of claim 2, which contains formula (1), but claim 4 recites “the compound of formula I” and the structure is labeled “III”. Appropriate correction is required. Allowable Subject Matter Claims 1-9 will be allowed if amended to overcome the objections and rejections under 35 U.S.C. 112, 2nd paragraph. The prior art does not teach or suggest the compounds, as claimed by the Applicant. Therefore, these claims will be allowed, if amended to overcome objections and rejection under 35 U.S.C. 112, second paragraph. EXAMINER NOTES Examiner notes that a signed IDS is attached to this Office Action. On August 7, 2026, Examiner reached out to Applicant to discuss the objections and rejections of claims under 35 USC 112, 2nd paragraph, to have applicant submit a supplemental amendment to address the rejection, but Applicant could not be reached. Conclusion Claims 1-9 are pending. Claims 1-9 are rejected. No claims are allowed. Again, the lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors and grammatical errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the claims and specification. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL V WARD/ Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Sep 26, 2022
Application Filed
Aug 27, 2025
Non-Final Rejection mailed — §112
Nov 25, 2025
Response Filed
Apr 14, 2026
Request for Continued Examination
Apr 20, 2026
Response after Non-Final Action
Aug 11, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747205
SULFUR-CONTAINING LIPIDS
3y 2m to grant Granted Sep 29, 2026
Patent 12734277
CONTROLLED-VISCOSITY POLYMERIC HYDROGEL AND METHOD FOR MAKING IT
4y 4m to grant Granted Sep 15, 2026
Patent 12714718
TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL
3y 11m to grant Granted Aug 25, 2026
Patent 12714659
COSMETIC
3y 5m to grant Granted Aug 25, 2026
Patent 12708609
METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION
2y 9m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
83%
Grant Probability
71%
With Interview (-12.2%)
2y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1704 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month